8-K: Foghorn Therapeutics Announces Promising Preclinical Data and Pipeline Updates at AACR 2025

Foghorn Therapeutics highlights preclinical data for FHD-909, selective CBP degrader, and selective EP300 degrader programs, along with a pipeline update, at the AACR 2025 Annual Meeting.

Summary

• Foghorn Therapeutics presented new preclinical data at the AACR 2025 Annual Meeting for several potential first-in-class medicines.
• FHD-909, a SMARCA2 selective inhibitor, is advancing in a Phase 1 trial for SMARCA4 mutated cancers, with NSCLC as the primary target.
• Preclinical data shows synergistic anti-tumor activity of FHD-909 in combination with pembrolizumab and KRAS inhibitors, supporting clinical exploration.
• Selective CBP degrader combination approaches show promise in preclinical ER+ breast cancer models.
• Further preclinical characterization of the therapeutic potential of the Selective EP300 degrader program to treat advanced hematological malignancies was presented.
• The company plans to provide an overview of its Selective ARID1B degrader program, a synthetic lethal target implicated in up to 5% of all solid tumors, with a program update expected in the second half of the year.

Sentiment

Score: 8

Explanation: The document presents positive preclinical data and pipeline updates, suggesting potential for future clinical success and market opportunities. The collaboration with Lilly and the well-funded status further contribute to a positive outlook.

Positives

• FHD-909 shows synergistic activity with standard-of-care chemotherapies, KRAS inhibitors, and pembrolizumab in NSCLC animal models.
• Selective CBP degraders have combinatorial benefits with approved chemotherapies and targeted agents in solid tumors beyond EP300-mutant cancers.
• Selective EP300 degradation shows promise as a well-tolerated and effective treatment strategy for advanced hematological malignancies.
• Foghorn has developed highly potent and selective binders to ARID1B and achieved selective degradation of ARID1B.

Risks

• The forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict.
• Actual results may differ materially from those contemplated by the forward-looking statements due to various factors, including those related to clinical trials and market conditions.

Future Outlook

Foghorn anticipates continued progress on its FHD-909 program in collaboration with Lilly and expects a program update on its Selective ARID1B degrader program in the second half of 2025.

Management Comments

• Adrian Gottschalk, President and Chief Executive Officer of Foghorn, stated that they are excited by the preclinical combination data of FHD-909 with chemotherapy, KRAS inhibitors, and pembrolizumab, which support further clinical exploration in NSCLC.
• Mr. Gottschalk also mentioned the presentation of initial preclinical data defining combination opportunities for the Selective CBP degrader program, including data in ER+ breast cancer.

Industry Context

The announcement highlights Foghorn's efforts to develop novel therapies targeting the chromatin regulatory system, an area implicated in a significant percentage of tumors, and positions the company as a leader in this field.

Comparison to Industry Standards

• The development of selective inhibitors and degraders for targets like SMARCA2, CBP, EP300, and ARID1B addresses challenges in selectivity and toxicity that have hindered previous attempts in the industry.
• The collaboration with Lilly, a leading oncology company, provides Foghorn with significant resources and expertise to advance its programs.
• The focus on genetically defined cancers and synthetic lethal strategies aligns with the growing trend of precision medicine in oncology.

Stakeholder Impact

• Shareholders: Positive preclinical data and pipeline updates may increase investor confidence.
• Patients: Potential for new treatment options for cancers with SMARCA4 mutations, ER+ breast cancer, and hematological malignancies.
• Employees: Continued progress in research and development may create opportunities for career advancement.

Next Steps

• Continued enrollment and dose escalation in the ongoing Phase 1 trial evaluating FHD-909.
• Further clinical exploration of FHD-909 in combination with pembrolizumab and KRAS inhibitors.
• Advancement of preclinical assets (Selective SMARCA2 Degrader, CBP, EP300, ARID1B) towards INDs.
• Program update on the Selective ARID1B degrader program expected in the second half of the year.

Key Dates

Keywords

FHD-909, SMARCA2 inhibitor, CBP degrader, EP300 degrader, ARID1B degrader, AACR, NSCLC, ER+ breast cancer, hematological malignancies, Foghorn Therapeutics, oncology, preclinical data